KRN 7000 (KRN7000)

01/01/2000 - "The KRN7000 administration resulted in a high percentage of cured mice, which acquired tumor-specific immunity. "
03/15/1998 - "KRN7000 administration resulted in a high percentage of cured mice that acquired tumor-specific immunity. "
01/01/1998 - "The in vivo administration of KRN7000 significantly augmented NK activity of hepatic MNC and inhibited tumor growth of EL-4 cells in the liver more markedly than chemotherapeutic agents, leading to a relatively high rate of cured mice. "
01/01/1998 - "In addition, it appeared that the KRN7000 treatment is effective in mice with established EL-4 tumors. "
12/01/2002 - "We performed a dose escalation study of KRN7000 in advanced cancer patients. "

03/15/1998 - "These results suggest that KRN7000 may be useful for the treatment of colorectal liver metastasis."
09/01/2003 - "Intraportal injection of KRN7000 exhibited a dense accumulation of CD4-CD8- natural killer T cells, around the liver metastases in vivo. "
08/01/2000 - "Adjuvant immunotherapy using KRN7000 could be a promising modality for the prevention of postoperative liver metastases."
01/01/1998 - "These results suggest that KRN7000 will be useful for the treatment of cancer liver metastasis."
05/01/2001 - "[KRN7000 inhibit hepatic metastasis of pancreatic cancer]."

01/01/1998 - "These results suggest that KRN7000 will be useful for the treatment of cancer liver metastasis."
01/01/2000 - "These results suggest that NK cells, NK1.1+ T (NKT) cells, cytotoxic T lymphocytes, and macrophages play an important role in killing tumor cells in the liver, and that KRN7000 may be useful for the treatment of cancer liver metastasis."

08/01/2008 - "We showed that KRN7000, injected before or within 2 h after LPS challenge, was able to prevent endotoxic shock. "
03/01/2007 - "A role of Th2 cytokines in counteracting LPS-induced shock was supported by experiments in which the protection against Shwartzman reaction by KRN7000 was abrogated by in vivo coadministration of anti-Th2 cytokines antibodies. "
08/01/2008 - "The NKT cell ligand alpha-galactosylceramide and its synthetic homologue KRN7000 stimulate rapid and copious secretion of IFN-gamma and TNF-alpha release, both of which are key mediators of LPS-induced shock. "
03/01/2007 - "alpha-galactosylceramide, a natural killer T cell ligand, and its synthetic homolog, KRN7000, consistently influence IFN-gamma and TNF-alpha release, both mediators of LPS-induced shock. "

03/01/2007 - "To modify the course of endotoxin shock, we injected KRN7000 at different time points of experimental systemic Shwartzman reaction. "
03/01/2007 - "A role of Th2 cytokines in counteracting LPS-induced shock was supported by experiments in which the protection against Shwartzman reaction by KRN7000 was abrogated by in vivo coadministration of anti-Th2 cytokines antibodies. "